Cormorant Asset Management as of Dec. 31, 2024
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 48 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 25.3 | $460M | 8.5M | 54.15 | |
| Praxis Precision Medicines I Com New (PRAX) | 7.2 | $130M | 1.7M | 76.96 | |
| Janux Therapeutics (JANX) | 6.2 | $112M | 2.1M | 53.54 | |
| Arcellx Common Stock (ACLX) | 5.5 | $100M | 1.3M | 76.69 | |
| Edgewise Therapeutics (EWTX) | 5.0 | $91M | 3.4M | 26.70 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 4.6 | $84M | 3.3M | 25.70 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 3.4 | $62M | 8.3M | 7.45 | |
| Rapport Therapeutics (RAPP) | 2.9 | $52M | 2.9M | 17.74 | |
| Crinetics Pharmaceuticals In (CRNX) | 2.8 | $51M | 1.0M | 51.13 | |
| Insmed Com Par $.01 (INSM) | 2.5 | $45M | 650k | 69.04 | |
| Bridgebio Pharma (BBIO) | 2.4 | $44M | 1.6M | 27.44 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.4 | $43M | 2.6M | 16.75 | |
| Bright Minds Biosciences Com New (DRUG) | 2.1 | $38M | 1.1M | 36.02 | |
| Vaxcyte (PCVX) | 1.9 | $35M | 425k | 81.86 | |
| Merus N V (MRUS) | 1.7 | $31M | 740k | 42.05 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.7 | $31M | 2.9M | 10.50 | |
| Avidity Biosciences Ord (RNA) | 1.7 | $31M | 1.1M | 29.08 | |
| Pharvaris N V (PHVS) | 1.5 | $28M | 1.5M | 19.17 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.5 | $28M | 2.4M | 11.80 | |
| Tarsus Pharmaceuticals (TARS) | 1.5 | $28M | 500k | 55.37 | |
| Axsome Therapeutics (AXSM) | 1.5 | $28M | 325k | 84.61 | |
| Arcutis Biotherapeutics (ARQT) | 1.4 | $25M | 1.8M | 13.93 | |
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $22M | 400k | 55.98 | |
| Cg Oncology (CGON) | 1.2 | $22M | 775k | 28.68 | |
| Cargo Therapeutics (CRGX) | 0.9 | $17M | 1.2M | 14.42 | |
| Alumis (ALMS) | 0.9 | $17M | 2.1M | 7.86 | |
| Onkure Therapeutics Com Cl A (OKUR) | 0.9 | $16M | 1.8M | 8.60 | |
| Arrivent Biopharma (AVBP) | 0.9 | $16M | 586k | 26.64 | |
| Abivax Sa Sponsored Ads (ABVX) | 0.9 | $16M | 2.1M | 7.32 | |
| Engene Holdings (ENGN) | 0.8 | $16M | 2.3M | 6.65 | |
| Bioage Labs (BIOA) | 0.8 | $15M | 2.6M | 5.79 | |
| Biomea Fusion (BMEA) | 0.8 | $14M | 3.6M | 3.88 | |
| Mbx Biosciences (MBX) | 0.7 | $13M | 700k | 18.43 | |
| Septerna (SEPN) | 0.7 | $13M | 560k | 22.90 | |
| Immunitybio (IBRX) | 0.4 | $7.7M | 3.0M | 2.56 | |
| Enliven Therapeutics (ELVN) | 0.3 | $5.6M | 250k | 22.50 | |
| Silverback Therapeutics (SPRY) | 0.3 | $5.3M | 500k | 10.55 | |
| Vyne Therapeutics (VYNE) | 0.3 | $4.7M | 1.4M | 3.35 | |
| Kala Bio Com New (KALA) | 0.2 | $4.2M | 603k | 6.94 | |
| Gh Research Ordinary Shares (GHRS) | 0.2 | $4.2M | 593k | 7.00 | |
| Y Mabs Therapeutics | 0.2 | $3.3M | 425k | 7.83 | |
| Urogen Pharma (URGN) | 0.2 | $3.2M | 300k | 10.65 | |
| Omeros Corporation (OMER) | 0.2 | $3.0M | 300k | 9.88 | |
| Stoke Therapeutics (STOK) | 0.2 | $2.8M | 254k | 11.03 | |
| Biohaven (BHVN) | 0.1 | $2.1M | 56k | 37.35 | |
| Verve Therapeutics (VERV) | 0.1 | $2.0M | 350k | 5.64 | |
| Artiva Biotherapeutics (ARTV) | 0.1 | $1.0M | 104k | 10.08 | |
| Rapt Therapeutics | 0.0 | $316k | 200k | 1.58 |
